Copyright © 2021. Inderes Oyj. All rights reserved.

Redeyes view on the Q1 report. With a report slightly above our estimates, we only make minor adjustments to our forecasts for the current year. We leave our Base case at SEK 340 unchanged.

Lähde: Finwire News

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China and Japan. The company derives the majority of its revenue from the sale of analyzers.